title: Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.
abstract: BACKGROUND
  Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA).
  
  
  OBJECTIVE
  To evaluate the long-term effects of colchicine and UDCA in symptomatic PBC patients.
  
  
  METHODS
  We extended up to 10 years the double-blind treatment of 44 symptomatic PBC patients originally included in a 3-year multicentre study comparing UDCA and colchicine (U + C) versus UDCA and placebo (U + P). Outcome measures were death or liver transplantation; incidence of clinically relevant events; clinical and quantitative variables retaining prognostic information.
  
  
  RESULTS
  Mean follow-up was 7 +/- 3 years. One patient was lost, three withdrew because of jaundice (U + P); two patients stopped colchicine but remained on UDCA. Eleven patients (two for liver-unrelated reasons, U + P) and six patients (U + C) died, three and two patients, respectively, were transplanted (incidence rate difference, five cases per 100 patient-years; 95% CI, -1 to 11). Hepatocellular carcinoma developed in one (U + P) and four (U + C) patients (difference, -2; CI, -5 to 1), portal hypertension complications in nine patients from each group (difference, 1; CI, -5 to 6). Trends of serum bilirubin, Mayo score, antipyrine clearance were similar among treatment groups.
  
  
  CONCLUSIONS
  In cirrhotic PBC patients, colchicine does not offer additional benefits to UDCA. In this population, UDCA does not obviate disease progression.
authors.affiliation: Department of Medicine, Surgery and Dentistry Ospedale San Paolo, School of Medicine San Paolo, University of Milan, Milan, Italy. battehsp@mailserver.unimi.it
authors.forename: P M
authors.initials: PM
authors.lastname: Battezzati
authors.forename: M
authors.initials: M
authors.lastname: Zuin
authors.forename: A
authors.initials: A
authors.lastname: Crosignani
authors.forename: M
authors.initials: M
authors.lastname: Allocca
authors.forename: P
authors.initials: P
authors.lastname: Invernizzi
authors.forename: C
authors.initials: C
authors.lastname: Selmi
authors.forename: E
authors.initials: E
authors.lastname: Villa
authors.forename: M
authors.initials: M
authors.lastname: Podda
mesh_terms: D003078:Colchicine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D007558:Italy; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D006074:Gout Suppressants; D014580:Ursodeoxycholic Acid; D003078:Colchicine